Effective Date 10/01/2025
Coverage Policy Number IP0576

Somapacitan

Table of Contents

Related Coverage Resources

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment where appropriate and have discretion in making individual coverage determinations. Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant criteria outlined in the applicable Coverage Policy, including covered diagnosis and/or procedure code(s). Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this Coverage Policy (see "Coding Information" below). When billing, providers must use the most appropriate codes as of the effective date of the submission. Claims submitted for services that are not accompanied by covered code(s) under the applicable Coverage Policy will be denied as not covered. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

OVERVIEW

Sogroya, a long-acting human growth hormone (hGH) analog, is indicated for the treatment of pediatric patients ≥ 2.5 years of age who have growth failure due to inadequate secretion of growth hormone (GH).[1] Sogroya is also indicated for the replacement of endogenous GH in adults with GH deficiency (GHD).

Disease Overview

GHD in Children and Adolescents

Sogroya is a hGH analog.[1] In children with GHD, somatropin is effective for increasing final adult height.[2] Somatropin therapy is recommended to normalize adult height and avoid extreme shortness in children and adolescents with GHD.[2] In addition to congenital causes, hypopituitarism may also be caused by radiation therapy; somatropin may be used to improve final height of children who have undergone radiation.[3,4]

GHD in Adults or Transition Adolescents

Somatropin is indicated for the replacement of endogenous GH in adults with GH, which may present in adults or children as GHD.[11] Patients with other anterior pituitary hormone deficiencies are likely to have GHD. In adults, the diagnosis of GHD usually is made in patients with signs and symptoms of hypothalamic-pituitary disease (endocrine, structural, and/or genetic causes); those who have received cranial irradiation or tumor treatment; or those with traumatic brain injury or subarachnoid hemorrhage.[11,12] Onset may be in adulthood or childhood. In childhood, the goal of somatropin therapy is primarily for statural growth. When final adult height is attained, somatropin therapy is no longer required for statural growth. Transition is used to describe the period in adolescence after growth is completed and the need for continued replacement into adulthood is assessed. Confirmatory GH stimulation testing may not be required in patients, such as those with congenital/genetic GHD or multiple pituitary hormone deficiencies. When persistent GHD is documented after completion of adult height, somatropin therapy should be continued to attain full skeletal and muscle maturation during the transition period from childhood to adulthood.[11] In adults with GHD, somatropin replacement therapy improves abnormalities in substrate metabolism, body composition, and physical and psychosocial function.[11,12] GH is not approved by the FDA for the treatment of other conditions in adults who may have a low GH response to GH provocative testing (such as obesity, aging, or depression) or to improve athletic performance.[3,5]

Macrilen (macimorelin oral solution) was the most recently approved test for the diagnosis of adult GHD. Patients in the pivotal trial were 18 to 66 years of age and the BMI ranged from 16 to 40 kg/m^2.[26] Safety and diagnostic performance have not been established in patients with BMI > 40 kg/m^2. Clinical studies established that a maximally stimulated serum growth hormone level of < 2.8 ng/mL (i.e., at the 30, 45, 60, and 90 minute time points) after Macrilen administration confirms the presence of adult GHD. Novo Nordisk no longer commercializes Macrilen. As of May 2023, Aeterna Zentaris/Cosciens Biopahrma regained the rights to macimorelin in the United States and is engaged in business development efforts to secure a new development and commercialization partner.[27]

Guidelines

A consensus statement from international experts was recently published (2025) regarding long-acting GH therapy.[28] The authors note that lonapegsomatropin, somapacitan, and somatrogon have all demonstrated noninferiority to daily somatropin for efficacy (i.e., annualized height velocity) in pediatric GHD. They also state that the safety profile of long-acting products is comparable to that of daily somatropin. It is noted that given the unique pharmacokinetic and pharmacodynamic profile and molecular weight of each formulation, the weight-based dosing calculation is different for each product and direct milligram dose comparisons are not appropriate. Some guidelines do not specifically address Sogroya. Neither the Pediatric Endocrine Society guidelines for children and adolescents with GH deficiency[2] (2016) nor the GH Research Society guidelines on children with short stature[15] (2019) recommend a specific GH product for GHD. Both publications note that newer long-acting GH preparations may reduce the frequency of injections.

The American Association of Clinical Endocrinologists and the American College of Endocrinology guidelines for management of GHD in adults and patients transitioning from pediatric to adult care[16] (2019) also do not prefer one GH agent over another. These guidelines state that when the clinician is suspicious of adult GHD, establishing a diagnosis is essential before replacement with GH. Adult GHD is associated with numerous adverse metabolic abnormalities (abdominal obesity, reduced lean body mass, increased peripheral insulin resistance, impaired cardiac performance) which may contribute to increased cardiovascular morbidity and mortality.

Coverage Policy

Documentation: Documentation is required where noted in the criteria. Documentation may include, but not limited to, chart notes, laboratory tests, claims records, and/or other information.

POLICY STATEMENT

Prior Authorization is required for benefit coverage of Sogroya. All reviews will be directed to a clinician (i.e., pharmacist or nurse) for verification of criteria. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Sogroya as well as monitoring required for adverse events and long-term efficacy, initial approval requires the medication to be prescribed by or in consultation with a physician who specializes in the condition being treated. Human growth hormone is FDA-approved for treatment of a limited number of conditions. The FDA has not approved the use of human growth hormone as therapy for anti-aging, longevity, cosmetic or performance enhancement. Federal law prohibits the dispensing of human growth hormone for non-approved purposes. A pharmacy's failure to comply with that law could result in significant criminal penalties to the pharmacy and its employees. Accordingly, a pharmacy may decline to dispense prescriptions for human growth hormone when written by a physician or other authorized prescribers who they believe may be involved in or affiliated with the fields of anti-aging, longevity, rejuvenation, cosmetic, performance enhancement, or sports medicine.

Somapacitan-beco subcutaneous injection (Sogroya) is considered medically necessary when ONE of the following is met:

1. **Growth Hormone Deficiency in a Child or Adolescent.** Individual meets **ALL** of the following criteria:
    - A. Age 2.5 years or older
    - B. **ONE** of the following:
        - i. Documentation of **BOTH** of the following:
            - a. Diagnostic evaluation including **BOTH** of the following:
                - I. Other pituitary hormone deficiencies (for example, thyroid, cortisol or sex steroids) have been ruled out and/or corrected prior to time of testing
                - II. At least **TWO** growth hormone stimulation tests performed with any of the following agents: levodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon **AND** both tests show a growth hormone response of less than 10 ng/mL
            - b. Auxologic evaluation (stature and growth velocity data) including **ONE** of the following:
                - I. Height is more than two [2] standards of deviation (SD) below average for the population mean height for age and sex, and **ONE** of the following:
                    1) One-year height velocity more than one standard of deviation (SD) below the mean for chronological age
                    2) 2 years of age or older, and there is a decrease in height of more than 0.5 standards of deviation (SD) over one year
                - II. One-year height velocity is more than two standards of deviation (SD) below the mean for age and sex
                - III. Height velocity is more than 1.5 standards of deviation (SD) below the mean sustained over two years

        - ii. Cranial or Whole Body irradiation

        - iii. **BOTH** of the following:
            - a. **ONE** of the following:
                - I. Defined central nervous system pathology (for example, empty sella syndrome, interruption of pituitary stalk, hypoplasia of the pituitary gland, craniofacial developmental defects, pituitary or hypothalamic tumors)
                - II. Undergone tumor resection
            - b. **ONE** of the following:

I. **ONE** growth hormone stimulation test with any of the following agents: levodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon **AND** the test shows a growth hormone response of less than 10 ng/mL
II. Deficiency in at least **ONE** other pituitary hormone (for example, adrenocorticotropic hormone, thyroid-stimulating hormone, gonadotropin [luteinizing hormone and/or follicle stimulating hormone deficiency are counted as one deficiency], or prolactin)

iv. Congenital hypopituitarism

v. Multiple pituitary hormone deficiencies and **BOTH** of the following:
a. **THREE** or more of the following pituitary hormone deficiencies: somatropin (growth hormone), adrenocorticotropic hormone, thyroid-stimulating hormone, gonadotropin (luteinizing hormone and/or follicle stimulating hormone deficiency are counted as one deficiency), and prolactin
b. **ONE** growth hormone stimulation test with any of the following agents: levodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon **AND** the test shows a growth hormone response of less than 10 ng/mL

Note: If the individual has had one growth hormone stimulation test and the peak growth hormone response was less than 10 ng/mL, this would satisfy criteria for an approval.

vi. Hypophysectomy (surgical removal of pituitary gland)

C. The medication has been prescribed by, or in consultation with, an endocrinologist
D. Preferred product criteria is met for the products listed in the below table(s)

2. **Growth Hormone Deficiency in an Adult or Transition Adolescent.** Individual meets **ALL** of the following criteria:
A. According to the prescriber, somatropin is not being prescribed for anti-aging therapy or to enhance athletic ability or for body building
B. Documented diagnosis of growth hormone deficiency based on **ONE** of the following:
i. Childhood onset
ii. Adult onset that results from **ONE** of the following:
a. growth hormone deficiency alone or multiple hormone deficiencies (hypopituitarism) resulting from pituitary disease
b. hypothalamic disease
c. pituitary surgery
d. cranial radiation therapy
e. tumor treatment
f. traumatic brain injury
g. subarachnoid hemorrhage
C. **ONE** of the following criteria:
i. Individual has known perinatal insults OR congenital or genetic defects
ii. **ALL** of the following:
a. Has or had **THREE** or more of the following pituitary hormone deficiencies prior to hormone replacement therapy (if hormone therapy is required): adrenocorticotropic hormone, thyroid-stimulation hormone, gonadotropin deficiency (luteinizing hormone and/or follicle stimulating hormone deficiency are counted as one deficiency), and prolactin
b. The age and gender adjusted serum insulin-like growth factor-1 is or was below the lower limit of the normal reference range for the reporting laboratory prior to growth hormone therapy

c. Other causes of low serum insulin-like growth factor-1 have been excluded (e.g., malnutrition, prolonged fasting, poorly controlled diabetes mellitus, hypothyroidism, hepatic insufficiency, oral estrogen therapy)
d. For an adult: Negative response to **ONE** of the following standard growth hormone stimulation tests:
    1) For insulin, levodopa, clonidine, arginine, or glucagon: growth hormone response of less than 5 ng/mL when measured by polyclonal antibody (RIA) or less than 2.5 ng/mL when measured by monoclonal antibody (IRMA) to one provocative stimuli of growth hormone release
    2) For macimorelin: **BOTH** of the following:
        I. Maximum serum growth hormone level observed after stimulation of less than 2.8 ng/ml for the 4 blood draws
        II. Body mass index (BMI) less than or equal to 40 kg/m^2

D. The medication has been prescribed by, or in consultation with, an endocrinologist
E. Preferred product criteria is met for the products listed in the below table(s)

Employer Drug Lists:

Product	Criteria
Sogroya (somapacitan-beco)	**Advantage/Value/Total Savings/Drug List Plans:** 1. Patient is 2.5 years of age or older **AND** has tried Skytrofa for 6 months OR experienced an intolerance with Skytrofa **[documentation required]** **Standard/Performance Drug List Plans:** Patient meets **ONE** of the following (1, 2 or 3): 1. Patient is < 3 years of age; OR 2. Patient is ≥ 3 years of age to < 18 years of age and meets ONE of the following (a or b): **a.** Patient has tried Ngenla for 6 months **[documentation required]**; OR **b.** Patient has experienced an intolerance with Ngenla **[documentation required]** **2.** Patients ≥ 18 years of age and meets BOTH of the following (A and B): **A.** Patient has tried BOTH of the following products: Genotropin and Omnitrope **[documentation required]**; AND **B.** Patient cannot continue to use each of the TWO products due to a formulation difference in the inactive ingredient(s) [e.g., differences in stabilizing agent, buffering agent, and/or surfactant] which, according to the prescriber, would result in a significant allergy or serious adverse reaction **[documentation required]**. Note: Meeting the criteria above with a trial of any daily growth hormone product(s) would count toward meeting the requirements regardless of formulary status **Legacy Drug List Plans:** Patient Meets **ONE** of the following (1, 2 or 3): 1. Patient is ≥ 2.5 years of age **AND** has tried Skytrofa for 6 months OR experienced an intolerance with Skytrofa **[documentation required]**; OR 2. Patient is ≥ 3 years of age to < 18 years of age **AND** has tried one of Skytrofa or Ngenla for 6 months OR

Product	Criteria
	experienced an intolerance with Skytrofa or Ngenla **[documentation required]**; OR 3. Patients ≥ 18 years of age and has tried Skytrofa for 6 months OR experienced an intolerance with Skytrofa **[documentation required]**

Individual and Family Plans:

Product	Criteria
Sogroya (somapacitan-beco)	Patient Meets **ONE** of the following (1 or 2): **1.** Patients ≥ 2.5 years of age to < 18 years of age and meets ONE of the following (A or B): **A.** Patient has been able to adhere to somatropin product(s) administered daily AND has experienced inadequate efficacy (i.e., patient has tried for 12 months and has a growth rate of less than 2 cm per year) **[documentation required]** with ONE product from the following list: Genotropin or Omnitrope; OR **B.** Patient meets BOTH of the following (i and ii): **i.** Patient has tried BOTH of the following products: Genotropin and Omnitrope **[documentation required]**; AND **ii.** Patient cannot continue to use each of the TWO products due to a formulation difference in the inactive ingredient(s) [e.g., differences in stabilizing agent, buffering agent, and/or surfactant] which, according to the prescriber, would result in a significant allergy or serious adverse reaction **[documentation required]**. **2.** Patients ≥ 18 years of age and meets BOTH of the following (A and B): **A.** Patient has tried BOTH of the following products: Genotropin and Omnitrope **[documentation required]**; AND **B.** Patient cannot continue to use each of the TWO products due to a formulation difference in the inactive ingredient(s) [e.g., differences in stabilizing agent, buffering agent, and/or surfactant] which, according to the prescriber, would result in a significant allergy or serious adverse reaction **[documentation required]**. Note: Meeting the criteria above with a trial of any daily growth hormone product(s) would count toward meeting the requirements regardless of formulary status

When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.

Receipt of sample product does not satisfy any criteria requirements for coverage.

Reauthorization Criteria

Continuation of somapacitan-beco (Sogroya) is considered medically necessary for **ALL** covered diagnoses when the above medical necessity criteria are met AND beneficial response is demonstrated by **ONE** of the following:

1. Less than 12 years of age: Height has increased by at least 2 cm/year in the most recent year
2. 12 years of age to 17 years of age and **BOTH** of the following:
    a. Height has increased by at least 2 cm/year in the most recent year
    b. Epiphyses are open
3. 18 years of age or older and **ALL** of the following:
    a. Height has increased by at least 2 cm/year in the most recent year
    b. Epiphyses are open
    c. Mid-parental height has not been attained

Authorization Duration

Initial approval duration is up to 12 months.
Reauthorization approval duration is up to 12 months.

Conditions Not Covered

Sogroya for any other use is considered not medically necessary, including the following (this list may not be all inclusive; criteria will be updated as new published data are available):

1. **Athletic Ability Enhancement.** Somatropin and related agents are not FDA-approved for athletic performance enhancement or for body building in non-athletes. Federal law prohibits the distribution or dispensing of somatropin or related agents for non-FDA approved uses.

2. **Central Precocious Puberty.** Children with precocious puberty are often treated with gonadotropin releasing hormone (GnRH) agonists (Lupron® [leuprolide acetate injection]) to suppress pituitary gonadal activity, to slow the advancement of bone age (prevent premature fusion of the epiphyseal growth plates), and to improve adult height. In some patients GnRH agonist therapy may result in marked deceleration of bone growth and may result in adult height that is less than the mid-parental height. Small and nonrandomized studies have demonstrated a significant improvement in final adult height over pre-treated predicted adult height in patients treated with GnRH agonist and GH as compared with patients treated with GnRH agonist alone. However, larger randomized studies are lacking, and routine use of GH in this setting is not recommended

3. **Congenital Adrenal Hyperplasia (CAH).** The Endocrine Society clinical practice guidelines on CAH due to steroid 21-hydroxylase deficiency recommend against the use of experimental treatment approaches outside of formally approved clinical trials. Children with predicted adult height standard deviation ≤ -2.25 may be considered for growth-promoting treatments in appropriately controlled trials.

4. **Constitutional Delay of Growth and Puberty.** These children have delayed skeletal maturation and pubertal development. Administering somatropin does not increase adult height (which is usually normal). Short-term androgen therapy accelerates growth and the rate of pubertal advancement in boys.

5. **Acute Critical Illness Due to Complications Following Surgery, Multiple Accidental Trauma, or with Acute Respiratory Failure.** In two placebo-controlled trials, in non-growth hormone deficient adults (n = 522) with these conditions, there was a significant increase in mortality (42% vs. 19%) in patients treated with somatropin compared to those on placebo.

6. **Aging (i.e., Antiaging); To Improve Functional Status in Elderly Patients; and Somatopause.** Somatropin is not FDA-approved for anti-aging therapy, to improve functional status in elderly patients, or to treat somatopause. Federal law prohibits the distribution or dispensing of somatropin for non-FDA approved uses. There are no long-term studies assessing somatropin efficacy and safety for anti-aging therapy. Short-
 term therapy with somatropin may improve some measures of body composition, including increased muscle mass, reduced total body fat, improved skin elasticity, and

reduced rate of bone demineralization, but does not have positive effects on strength, functional capacity, or metabolism. Somatropin is associated with considerable adverse effects in non-growth hormone deficient adults (e.g., carpal tunnel syndrome, soft tissue edema, arthralgias, glucose intolerance, increased serum lipids). Another concern is the possible increased risk of cancer with long-term use of somatropin and the potentiating effects of IGFs on cancer. Somatropin is not indicated for the age-related decrease in growth hormone/IGF-1 status.

7. **Chronic Fatigue Syndrome.** There is no evidence of GHD in chronic fatigue syndrome.

8. **Corticosteroid-Induced Short Stature.** This includes a variety of chronic glucocorticoid-dependent conditions, such as asthma, Crohn's disease, juvenile rheumatoid arthritis, as well as after renal, heart, liver, or bone marrow transplantation. Short-term improvement in growth velocity in children with glucocorticoid-induced suppression has been reported with somatropin therapy. Long-term data are not available. Children being considered for treatment with somatropin should be enrolled in studies that allow careful monitoring and data analysis.

9. **Fibromyalgia.** In one placebo-controlled study, 120 non-GHD adult women with severe fibromyalgia and low levels of IGF-1 were randomized to somatropin 0.006 mg/kg/day for 12 months (dose was adjusted) or placebo for 6 months. Patients receiving placebo initially were switched to somatropin from Months 6 to 12 (open label). Standard therapy for fibromyalgia was continued. After 6 months, there were no differences between somatropin and placebo in the percentage of patients with fewer than 11 positive tender points, mean number of tender points, intensity of pain in every point evaluated, and other measures. After 12 months of somatropin therapy, 53% of patients had less than 11 positive tender points compared with 33% of patients who received placebo and then somatropin for 6 months ($P < 0.05$). At 18 months follow-up evaluation when somatropin was discontinued, impairment in pain perception worsened in both groups but to a lesser extent in the patients on somatropin for 12 months. Further controlled trials are needed with a longer duration, with different doses, and using the 2010 American College of Rheumatology criteria for fibromyalgia. Some patients with fibromyalgia may have adult GHD.

10. **Human Immunodeficiency Virus (HIV)-Infected Patients with Alterations in Body Fat Distribution** (e.g., increased abdominal girth, lipodystrophy and excess abdominal fat, buffalo hump). Somatropin is not indicated for the treatment of HIV-associated adipose redistribution syndrome (HARS). HARS is a subset of HIV lipodystrophy and is defined as maldistribution of body fat characterized by central fat accumulation (lipohypertrophy) with or without lipoatrophy. In HARS, fat may also accumulate in the upper body subcutaneous area such as the dorsocervical area (buffalo hump). These changes may be associated with metabolic disturbances (insulin resistance, glucose intolerance, dyslipidemia) and belly image distress. Safety and efficacy are not established.

11. **Infertility**. Some trials have demonstrated that GH intervention is associated with improved in-vitro fertilization (IVF) reproductive outcome, but others have concluded there is no evidence of an increased chance of a live birth with use of somatropin. More randomized controlled clinical trials with rigorous methodology are needed to confirm the beneficial effects of GH on assisted reproductive technology outcomes.[23] A 2025 phase III open-label study showed that empiric adjunvant GH therapy in GnRH antagonist cycles does not improve IVF stimulation results or reproductive outcomes, including implantation, miscarriage, and clinical pregnancy rates.[22]

12. **Obesity.** Somatropin is not indicated for the treatment of obesity. Low growth hormone levels are a consequence of central obesity and not a cause. Obesity is associated with decreased basal and pusatile release of growth hormone and decreased stimulated growth hormone release. Somatropin therapy does not have significant beneficial effects on obesity in persons without GHD and does not produce significant overall weight loss. Supraphysiologic doses of somatropin have been used to treat obesity. Effects of long-term therapy with somatropin are unknown.

13. **Osteoporosis.** Guidelines for treatment or prevention of osteoporosis do not include recommendations for use of somatropin. In one double-blind trial, 80 postmenopausal women with osteoporosis (56% of patients [n = 45/80] had a history of fractures) were randomized to somatropin 0.33 mg/day or 0.83 mg/day or to placebo for three years.50 The double-blind phase was 18 months and patients on somatropin continued drug for another 18 months and patients on placebo stopped at 18 months. Patients were compared with an age matched random population sample of women (n = 120). All patients received calcium 750 mg, vitamin D 400 units, and hormone replacement therapy. All women were followed for 10 years total. Bone mineral density increased in the patients receiving somatropin at years 4 and 5, and after 10 years, had decreased to similar levels as before treatment. At 10 years, 28% of women (n = 22/80) had had fractures. In the control group, fractures increased from 8% of patients at baseline to 32% of patients after 10 years. At 10 years, 41% of patients (n = 33/80) had stopped hormone replacement therapy; 23% had started bisphosphonates due to fractures, and 3% had received Forteo® (teriparatide injection). Larger studies are needed to determine the effects of somatropin therapy on bone mineral density and fractures in non-growth hormone deficient persons.

14. **Other Off-label Uses [for example, celiac disease, chromosomal anomalies unless otherwise specified as covered (for example, but not limited to, deletion of chromosome 18q), Crohn's disease, cystic fibrosis, Down syndrome, hypophosphatemic rickets, juvenile rheumatoid arthritis, muscular dystrophy, primary or idiopathic IGF-1 deficiency, skeletal dysplasias, spinal cord defects].** There is insufficient evidence in the peer-reviewed published scientific literature to support the safety and efficacy of growth hormone therapy in these conditions. Additionally, federal law prohibits the distribution or dispensing of somatropin for non-FDA approved uses.

References

1. Sogroya® subcutaneous injection [prescribing information]. Plainsboro, NJ: Novo Nordisk; February 2025.
2. Grimberg A, DiVall SA, Polychronakos C, et al; Drug and Therapeutics Committee and Ethics Committee of the Pediatric Endocrine Society. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. *Horm Res Paediatr*. 2016;86(6):361-397.
3. Melmed S. Idiopathic adult growth hormone deficiency. *J Clin Endocrinol Metab.* 2013;98:2187-2197.
4. Isfan F, Kanold J, Merlin E, et al. Growth hormone treatment impact on growth rate and final height of patients who received HSCT with TBI or/and cranial irradiation in childhood: a report from the French Leukaemia Long-Term Follow-Up Study (LEA). *Bone Marrow Transplant.* 2012;47:684-693.
5. Clemmons DR, Molitch M, Hoffman AR, et al. Growth hormone should be used only for approved indications. *J Clin Endocrinol Metab.* 2014;99:409-411.
6. Chen M, Eugster EA. Central Precocious Puberty: Update on diagnosis and treatment. *Paediatr Drugs*. 2015;17(4)272-81.
7. Shi Y, Ma Z, Yang X, et al. Gonadotropin-releasing hormone analogue and recombinant human growth hormone treatment for idiopathic central precocious puberty in girls. *Front Endocrinol.* 2023; 13:1085385.
8. Lin-Su K, Harbison MD, Lekarev O, et al. Final adult height in children with congenital adrenal hyperplasia treated with growth hormone. *J Clin Endocrinol Metab.* 2011;96:1710-1717.
9. Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.* 2018:103(11):4043-4088.
10. De Luca F, Argente J, Cavallo L, et al; International Workshop on Management of Puberty for Optimum Auxological Results. Management of puberty in constitutional delay of growth and puberty. *Pediatr Endocrinol Metab.* 2001;14 Suppl 2:953-957.
11. Molitch ME, Clemmons DR, Malozowski S, et al; Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2011;96:1587-1609.

12. Ho KK; 2007 GH Deficiency Consensus Workshop Participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. *Eur J Endocrinol.* 2007;157:695-700.
13. Krantz E, Trimpou P, Landin-Wilhelmsen K. Effect of growth hormone treatment on fractures and quality of life in postmenopausal osteoporosis: A 10-Year follow-up study. *J Clin Endocrinol Metab*. 2015;100:3251-3259.
14. Gillberg P, Mallmin H, Petren-Mallmin M, et al. Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis. *J Clin Endocrinol Metab.* 2002;87:4900-4906.
15. Collett-Solberg PF, Ambler G, Backelijaw PF, et al. Diagnosis, genetics, and therapy of short stature in children: A growth hormone research society international perspective. *Horm Res Paediatr.* 2019;92(1):1-14.
16. Yuen K, Biller B, Radovick S, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. *Endocr Pract.* 2019;25(11):1191-1232.
17. Vance ML. Can growth hormone prevent aging? *N Engl J Med*. 2003;348:779-780.
18. Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. *Ann Intern Med.* 2007;146:104-115.
19. Cleare AJ, Sookdeo SS, Jones J, et al. Integrity of the growth hormone/insulin-like growth factor system is maintained in patients with chronic fatigue syndrome. *J Clin Endocrinol Metab.* 2000;85:1433-1439.
20. Cuatrecasas G, Alegre C, Fernandez-Solà J, et al. Growth hormone treatment for sustained pain reduction and improvement in quality of life in severe fibromyalgia. *Pain.* 2012;153:1382-1389.
21. Geenen R, Jacobs JW, Bijlsma JW. Evaluation and management of endocrine dysfunction in fibromyalgia. *Rheum Dis Clin North Am*. 2002;28:389-404.
22. Mourad A, Jamal W, Hemmings R, et al. Empirical use of growth hormone in IVF is useless: the largest randomized controlled trial. *Hum Reprod.* 2025;40(1):77-84.
23. Chang CW, Sung YW, Hsueh YW, et al. Growth hormone in fertility and infertility: Mechanism of action and clinical applications. 2022;13:1040503.
24. Shadid S, Jensen MD. Effects of growth hormone administration in human obesity. *Obes Res.* 2003;11:170-175.
25. Mekala KC, Tritos NA. Effects of recombinant human growth hormone therapy in obesity in adults: a meta-analysis. *J Clin Endocrinol Metab.* 2009;94:130-137.
26. Macrilen™ oral solution [prescribing information]. Plainsboro, NJ: Novo Nordisk; July 2021.
27. Cosciens BioPharma. Product Publicationns 2024. Available at: Our Product | COSCIENS BIO. Accessed on June 12, 2025.
28. Maniatis A, Cutfield W, Dattani M, et al. Long-acting growth hormone therapy in pediatric growth hormone deficiency: A consensus statement. *J Clin Endocrinol Metab.* 2025;110(4):e1232-e1240.

Revision Details

Type of Revision	Summary of Changes	Date
Selected Revision	**Updated** Individual and Family Plan preferred product requirements.	01/01/2025
Selected Revision	**Updated** the Employer Plans preferred product requirements.	07/01/2025
Annual Revision	The following statement in the Policy Statement was updated to include a clinician nurse: "All reviews will be directed to a clinician (i.e., pharmacist or nurse) for verification of criteria."	10/01/2025

	Growth Hormone Deficiency in a Child or Adolescent: The wording “at least” was added to the requirement for two growth hormone stimulation tests < 10 ng/mL. **Growth Hormone Deficiency in Adult or Transition Adolescent:** The criterion “THREE or more of the following pituitary hormone deficiencies” was updated to “Has or had THREE or more of the following pituitary hormone deficiencies prior to hormone replacement therapy (if hormone therapy is required)” The criterion “The age and gender adjusted serum insulin-like growth factor-1 is below the lower limit of the normal reference range for the reporting laboratory” was updated to “The age and gender adjusted serum insulin-like growth factor-1 is or was below the lower limit of the normal reference range for the reporting laboratory prior to growth hormone therapy”. **Conditions Not Covered:** Updated information for Central Precocious Puberty and Infertility **Updated** Employer Plans and Individual and Family Plan preferred product table	

The policy effective date is in force until updated or retired.